HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Spada, A. Articles by Faglia, G. Search for Related Content PubMed Articles by Spada, A. Articles by Faglia, G.

Cellular alterations in pituitary tumors

Spada A, Vallar L, Faglia G. Cellular alterations in pituitary tumors. Eur J Endocrinol 1994;130:43–52. ISSN 0804–4643

In the last few years, molecular studies on pituitary adenomas have yielded evidence supporting a primary pituitary origin of these tumors. Although the existence of genomic alterations in tumoral cells is strongly suggested by the fact that almost all pituitary adenomas are monoclonal in origin, structural genetic abnormalities such as rearrangement, deletion or mutation, which could result in transcriptional activation, have been identified in a minority of tumors. As far as the possible loss of anti-oncogenes in pituitary tumors is concerned, gene alterations have not been found in the p53 nor in the retinoblastoma gene, while loss of chromosome 1 1q13 sequences, which contain the deduced location of the yet uncloned MEN-1 gene, has been reported in a subset of GH-secreting adenomas. With regard to the activation of dominant oncogenes in the process of tumor formation, activating mutations of either the Gs -subunit or the ras gene have been identified in a large proportion of GH-secreting adenomas and in individual particularly invasive tumours, respectively. Promoting agents such as hypothalamic neurohormones and growth factors may be required for the selective growth of genetically altered cells. In this respect, it is worth noting that receptor/postreceptor alterations occurring in pituitary tumors may cause an increased action of stimulatory neurohormones with growth promoting properties as well as defective action of inhibitory inputs.

Anna Spada, Institute of Endocrine Sciences, Pad. Granelli Ospedale Maggiore IRCCS, via F Sforza 35, Milano 20122, Italy

This article has been cited by other articles:

				N. Ben-Jonathan and R. Hnasko Dopamine as a Prolactin (PRL) Inhibitor Endocr. Rev., December 1, 2001; 22(6): 724 - 763. [Abstract] [Full Text] [PDF]

				T. H. Jones, S. K. Justice, and A. Price Suppression of Tyrosine Kinase Activity Inhibits [3H]Thymidine Uptake in Cultured Human Pituitary Tumor Cells J. Clin. Endocrinol. Metab., July 1, 1997; 82(7): 2143 - 2147. [Abstract] [Full Text] [PDF]

				I. Shimon and S. Melmed Pituitary Tumor Pathogenesis J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1675 - 1681. [Full Text] [PDF]